BioSpace News Archive

Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2022 on August 11, prior to the opening of trading on the New York Stock Exchange.

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that its DERMAdoctor product collections will be featured at Cosmoprof North America, a leading business-to-business (B2B) beauty trade show being held July 12-14 at the Las Vegas Convention Center.

Parkinson Canada in partnership with the Davis Phinney Foundation is excited to launch the first Canadian version of the Every Victory Counts® manual, a comprehensive resource aimed at helping the 100,000 Canadians living with Parkinson’s to maintain and improve their quality of life.

Meridian Bioscience, Inc. (“Meridian” or the “Company”) (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022.

SELLAS Life Sciences Group, Inc. today announced that the Company has added a second, once-a-week dose cohort in its ongoing global Phase 1 clinical trial in both the United States and China with the highly selective CDK9 inhibitor GFH009 for patients suffering from advanced relapsed or refractory lymphoma and acute myeloid leukemia (AML).

Meridian Bioscience, Inc and SD Biosensor, Inc. (“SDB”) (KOSE: A137310) and SJL Partners LLC (“SJL”) (collectively, the “Consortium”) announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53 billion.

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022.

The rising prevalence of various cancer types is a prime factor augmenting the growth of the global physiological saline market.

TORONTO, July 07, 2022 (GLOBE NEWSWIRE) -- ACTO , the omnichannel learning and enablement platform for life sciences, today announced the closing of a US$18 million equity financing. The investment was led by Questa Capital , a healthcare venture growth equity firm that actively invests in healthcare and life sciences software. With this investment, Questa joins ACTO’s existing investors: Resolve Growth Partners, Salesforce Ventures, Panache Ventures, and MaRS Investment Accelerator Fund 1 .

RIVANNA®, developers of world-first, imaging-based medical solutions, has named Nikki Troiano Gainey, a MedTech corporate and marketing strategy leader, to its board of directors.